Centessa Pharmaceuticals (CNTA) Gains from Investment Securities (2022 - 2026)
Centessa Pharmaceuticals (CNTA) reported Gains from Investment Securities of $3.7 million for Q1 2026, down 16.77% year-over-year from $4.4 million in Q1 2025, and up 1976.14% quarter-over-quarter from $176000.0 in Q4 2025.
Centessa Pharmaceuticals (CNTA) Gains from Investment Securities (2022 - 2026) Analysis & Trends
Centessa Pharmaceuticals (CNTA) has 5 years of Gains from Investment Securities data on file, last reported at $3.7 million in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $3.7 million, down 16.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.1 million (down 58.23% YoY), and the FY2025 annual result was $4.8 million, down 9.91% from the prior year.
- Gains from Investment Securities grew to $3.7 million in Q1 2026 per CNTA's latest filing, from $176000.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $9.7 million in Q1 2023 and troughed at -$206000.0 in Q4 2022.
- A 5-year average of $2.3 million and a median of $1.3 million in 2024 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2025 and 2026: Gains from Investment Securities slumped 96.38% in 2025, then dropped 16.77% in 2026.
- A 5-year view of Gains from Investment Securities shows it stood at -$206000.0 in 2022, then soared by 4814.08% to $9.7 million in 2023, then sank by 83.66% to $1.6 million in 2024, then plunged by 88.91% to $176000.0 in 2025, then jumped by 1976.14% to $3.7 million in 2026.
- Business Quant data shows CNTA's Gains from Investment Securities at $3.7 million in Q1 2026, $176000.0 in Q4 2025, and $125000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Centessa Pharmaceuticals | 6.15 Bn | 6.15 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.65 Mn |
| Mar 31, 2026 | 3.65 Mn |
| Dec 31, 2025 | 176,000.00 |
| Dec 31, 2025 | 176,000.00 |
| Sep 30, 2025 | 125,000.00 |
| Sep 30, 2025 | 125,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 4.39 Mn |
| Mar 31, 2025 | 4.39 Mn |
| Dec 31, 2024 | 1.59 Mn |
| Dec 31, 2024 | 1.59 Mn |
| Sep 30, 2024 | 970,000.00 |
| Sep 30, 2024 | 970,000.00 |
| Jun 30, 2024 | 2.76 Mn |
| Jun 30, 2024 | 2.76 Mn |
| Mar 31, 2023 | 9.71 Mn |
| Mar 31, 2023 | 9.71 Mn |
| Dec 31, 2022 | -206,000.00 |
| Dec 31, 2022 | -206,000.00 |